Recombinant activated Factor VII for prevention and treatment of intraventricular haemorrhage in neonates
Editorial Group: Cochrane Neonatal Group
Published Online: 16 MAR 2011
Assessed as up-to-date: 25 DEC 2010
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Malhotra A, Veldman A. Recombinant activated Factor VII for prevention and treatment of intraventricular haemorrhage in neonates (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD009032. DOI: 10.1002/14651858.CD009032.
- Publication Status: New
- Published Online: 16 MAR 2011
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the efficacy and safety of recombinant activated factor VII in the prevention or treatment of intraventricular haemorrhage in premature infants.
The secondary objective is to perform subgroup analyses based on:
- dose (low versus high), frequency (4 versus 6 hourly) and duration (3 versus 5 days) of rVIIa;
- gestational age in the prevention (less than 26 weeks versus 26 weeks or more) and treatment (less than 26 weeks versus 26 weeks or more) studies;
- status of IVH (known or unknown) at enrolment in prevention studies.